As previously noted in glioblastoma and melanoma cells, pro-survival pathways in these tumor types are activated in part by MC4R signaling, and its pharmaceutical anticancer efficacy is correlated with the activation of ERK1/2 [15,16]. This evidence concerns the gene MAPK3 and melanoma.